BSE - Delayed Quote INR

Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)

Compare
459.40 -27.05 (-5.56%)
At close: 3:28 PM GMT+5:30
Loading Chart for JAGSNPHARM.BO
DELL
  • Previous Close 486.45
  • Open 477.35
  • Bid 454.55 x --
  • Ask 455.35 x --
  • Day's Range 452.35 - 496.50
  • 52 Week Range 270.05 - 499.60
  • Volume 5,904
  • Avg. Volume 9,516
  • Market Cap (intraday) 12.167B
  • Beta (5Y Monthly) 1.14
  • PE Ratio (TTM) 60.93
  • EPS (TTM) 7.54
  • Earnings Date Oct 23, 2024
  • Forward Dividend & Yield 5.00 (1.03%)
  • Ex-Dividend Date Sep 6, 2024
  • 1y Target Est --

Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.

www.jagsonpal.com

1,025

Full Time Employees

March 31

Fiscal Year Ends

Recent News: JAGSNPHARM.BO

View More

Performance Overview: JAGSNPHARM.BO

Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

JAGSNPHARM.BO
19.94%
S&P BSE SENSEX
11.05%

1-Year Return

JAGSNPHARM.BO
10.56%
S&P BSE SENSEX
22.67%

3-Year Return

JAGSNPHARM.BO
199.64%
S&P BSE SENSEX
31.67%

5-Year Return

JAGSNPHARM.BO
1,941.78%
S&P BSE SENSEX
104.13%

Compare To: JAGSNPHARM.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: JAGSNPHARM.BO

View More

Valuation Measures

Annual
As of 10/21/2024
  • Market Cap

    12.88B

  • Enterprise Value

    11.49B

  • Trailing P/E

    64.52

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.22

  • Price/Book (mrq)

    6.87

  • Enterprise Value/Revenue

    5.51

  • Enterprise Value/EBITDA

    35.57

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.67%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.1B

  • Net Income Avi to Common (ttm)

    203.13M

  • Diluted EPS (ttm)

    7.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.48B

  • Total Debt/Equity (mrq)

    4.77%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: JAGSNPHARM.BO

View More

Company Insights: JAGSNPHARM.BO

Research Reports: JAGSNPHARM.BO

View More

People Also Watch